Global Initiative To Demonstrate Operational Excellence in Nigeria for Metastatic Colorectal Cancer Patients

October 29, 2025 7:00 AM

Bristol-Myers Squibb Company - Recently, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide an immunotherapy drug used to treat cancer. The goal of the initiative is to develop an approach that explores sustainable and effective administration of innovative immuno-oncology therapies in low- and middle-income countries.The ICM initiative is a...

Read more

Santa Barbara City College Partners with Mentavi Health to Deliver Rapid, Clinically Validated ADHD Evaluations for Students

October 29, 2025 6:00 AM

Santa Barbara City College (SBCC) is adopting Mentavi Health's Diagnostic Evaluation to provide timely, rigorous ADHD assessments for students seeking academic accommodations. The partnership enables SBCC to reach accommodation decisions faster, when appropriate, and helps students stay on course during the term's most demanding weeks.ADHD is the second-largest eligibility category for SBCC's Disability Services and Programs for Students (DSPS)....

Read more

Lex LasVegas to Emcee Compassion Center's Coalition for Patient Rights Inaugural Hoedown, Nov. 15 at Paradise Recreation Center

October 29, 2025 6:00 AM

The Compassion Center today announced that Lex LasVegas-comedian, creator, and host of The 4Horsemen of Comedy-will emcee the Compassion Center's Coalition for Patient Rights (CPR) Inaugural Charity Hoedown on Saturday, November 15, 2025, from 10:00 a.m. to 6:00 p.m. at Paradise Recreation Center, 4775 McLeod Dr., Las Vegas, NV 89121. The daylong, family-oriented event blends entertainment with actionable patient-rights education to advance a...

Read more

Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025

October 29, 2025 5:10 AM

Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast detailsDate: Wednesday, 05 November 2025Time: 2.00 pm CET (01.00...

Read more

Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 25 million to Advance Tumorad

October 29, 2025 4:00 AM

Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Board of Directors of Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") has today, with the support of the authorization received at the Annual General Meeting on May 14, 2025, resolved on a new issue of shares with preferential rights for the Company's existing shareholders of approximately SEK 25 million before issue costs (the "Rights Issue"). The purpose of the Rights Issue...

Read more

Senzime Q3 2025: Strong Growth and Clear Steps Towards Profitability

October 29, 2025 3:50 AM

Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - September 2025 is now available on the company's website www.senzime.com .Strategic events during and after the end of the third quarterAdditional strategic hospital contracts secured in the U.S. market.First-ever guidelines issued for neuromuscular monitoring in children undergoing anesthesia.Senzime's licensee Fukuda Denshi receives FDA and UKCA approvals for...

Read more

Spago Nanomedical Interim Report January-September 2025

October 29, 2025 3:20 AM

Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 14 (KSEK 485)The loss for the quarter amounted to KSEK -6,265 (KSEK -8,763)Operating expenses for the quarter amounted to KSEK -7,568 (KSEK -10,650)Earnings per share, before and after dilution, for the quarter amounted to SEK -0.02 (SEK -0.03)Cash and cash equivalents at the end of the quarter amounted to KSEK 11,257 (KSEK...

Read more

Hemogenyx Pharmaceuticals PLC Announces Clinical Trial Update and Grant of Share Awards

October 29, 2025 3:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that the independent Data Safety Monitoring Board ("DSMB") overseeing the Company's ongoing Phase I clinical trial of HG-CT-1, its proprietary Chimeric Antigen Receptor T-cell (CAR-T) therapy for the treatment of relapsed or refractory acute myeloid leukemia ("R/R AML") in adults, has reviewed safety data from the first three patients treated at the initial dose level and has...

Read more

IRLAB Publishes Interim Report for The Period January - September 2025

October 29, 2025 2:20 AM

IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company's interim report for the period January - September 2025, has been published.KEY HIGHLIGHTS DURING AND AFTER THE THIRD QUARTERIn July, the company announced the outcome of the rights issue. With a subscription rate of approximately 61.1 percent and guarantee undertakings of approximately...

Read more

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

October 29, 2025 2:20 AM

RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive results from its pivotal bioequivalence clinical study evaluating RLF-OD032, Relief's innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, for the treatment of...

Read more

Prepare for 340B's Rebate Model Pilot Program

October 28, 2025 5:05 PM

Rural hospitals in the 340B program are about to feel a new financial pressure. On January 1, 2026, HRSA's 340B Rebate Model Pilot Program will kick off, eliminating upfront discounts on 10 popular medications."With this change, pharmacies of covered entities will need to buy these medications at full price, then submit transactions data to receive rebates from manufacturers within 45 days of purchase," states Matthew Wright, 340B Account...

Read more

Desert Oasis Healthcare Expands Maternal Health Resources with New Maternal Health Educator Position and Updated Video Education Series

October 28, 2025 4:50 PM

Desert Oasis Healthcare (DOHC) is proud to announce a new addition to our highly-viewed online Maternal Education Video Series, designed to support expecting and new mothers with accessible, practical resources on pregnancy, childbirth, and early parenthood.Sandra Artinian, BSN, RN, DOHC's new Maternal Health Educator, recently joined the healthcare team with the goal of expanding maternal wellness support across the Coachella Valley and beyond....

Read more

Beauty-Stem's "Beauty Beyond Age" Forum

October 28, 2025 4:00 PM

On September 27, 2025, Beauty-Stem Biomedical US, a regenerative wellness brand that has successfully expanded into the North American market, hosted its "Beauty Beyond Age" medical forum in Southern California.The event gathered leaders from medicine, beauty, philanthropy, and media to explore how regenerative science can help women over 40 navigate the challenges of menopause-restoring balance, vitality, and confidence through evidence-based...

Read more

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

October 28, 2025 2:10 PM

Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ:SBFM) is quickly establishing which side of that line it's on. After scoring another major regulatory win, that position certainly isn't one of many in the crowd. On Tuesday, the company announced that it had secured Health Canada authorization to commercialize domperidone through its Nora Pharma subsidiary, a milestone that not only expands its commercial...

Read more

Who is Javad Sajan?

October 28, 2025 12:00 PM

(Allure Esthetic) - Dr. Javad Sajan is a world-renowned plastic surgeon widely regarded as the best plastic surgeon in Seattle and the top cosmetic surgeon in Washington State. As the founder of Seattle's Allure Esthetic Plastic Surgery, Dr. Sajan has earned international recognition for his surgical expertise and innovative techniques. He has been featured by major media outlets, including CNN, Cosmopolitan magazine, and ABC News affiliates,...

Read more

Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA

October 28, 2025 10:20 AM

Exousia Pro, Inc. (formerly Marijuana, Inc.) (OTCPINK:MAJI), a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is pleased to announce it has received Orphan Drug Designation from the FDA, for malignant Glioma, aka Glioblastoma multiforme (GBM).Exousia Pro's subsidiary, Exousia AI, along with Dr. Marvin S. Hausman, filed for Orphan Drug Designation last year for its exosome-based GBM treatment. The ODD...

Read more

Medical Care Technologies Inc. (OTC PINK:MDCE) Nears Completion of AI-Powered App Targeting the $4.5 Billion Global Nutrition & Recipe Market

October 28, 2025 9:30 AM

Medical Care Technologies Inc. (OTC PINK:MDCE) announced today that its first AI-driven mobile application, [App Name Pending Trademark], has entered its final development phase. The app uses image recognition to create recipes and also analyzes nutrition data directly from food photos. MDCE plans to deploy the app in 175 countries and in over 30 languages. According to industry research, the global diet & nutrition apps market is valued at...

Read more

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

October 28, 2025 9:00 AM

Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that the method of use patent (U.S. Patent No. 7,538,116) for EXXUATM (gepirone) extended-release tablets ("EXXUA") has been extended through September 2, 2030 under 35 U.S.C. 156. The patent extension further...

Read more

Modular Medical Announces Ongoing Progress to Obtain CE Mark

October 28, 2025 8:30 AM

Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery, today announced that it is continuing to progress toward CE Mark certification under the European Union Medical Device Regulation ("EU MDR 2017/745"). As part of this process, the Company is pleased to announce the successful completion of its Stage 1 ISO 13485:2016 audit, conducted by BSI, its Notified Body and Registrar.The audit...

Read more

VSee Awarded US Department of Health & Human Services FedRAMP High ATO

October 28, 2025 8:20 AM

VSee Health, Inc. (Nasdaq:VSEE) (the "Company"), announced it has received its Authority to Operate (ATO) at the FedRAMP High level from the U.S. Department of Health and Human Services (HHS). The authorization also allows other federal agencies to use VSee where FedRAMP High is required. The platform enables government partners to increase healthcare accessibility in remote locations and relieve medical surge events withenterprise-grade...

Read more